secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001651308-24-000043
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene provides additional 2023 financial data including regional gross margins and product R&D
--------------------------------------------------------------------------------

- Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).
- R&D expense by product: zanubrutinib $158M, tislelizumab $84M, pamiparib $9M, ociperlimab $78M.
- Total R&D expenses $1.78B in 2023 vs $1.64B in 2022; internal R&D $1.13B.
- Key products produced 5.0M vials, sold 3.88M vials; inventory 2.67M vials as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/0001651308-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/bgne-20240426.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer